A Study of Tirzepatide in Participants With Impaired Liver Function

NCT03940742 · Completed

Last updated 2026-05-28

This study is testing how the drug tirzepatide is processed in the body of adults with liver problems.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 32 people

Who can join Ages 18–85 · all sexes Healthy volunteers accepted.

Timeline Started 2019-07 · est. completion 2020-09

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT03940742 ↗

Description as written by the study sponsor.

The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC

Main thing measured	Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide
Sponsor	Eli Lilly and Company
Conditions studied	Hepatic Insufficiency
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03940742 ↗